Skip to main content

Retinal Vein Occlusion clinical trials at University of California Health

3 in progress, 1 open to eligible people

Showing trials for
  • Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

    “A study about serious vision loss caused by Central Retinal Vein Occlusion (CRVO) now open. Learn more to see if you may qualify!”

    open to eligible people ages 18 years and up

    This study evaluates whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO). Half of the participants will receive immediate cellular therapy followed by sham therapy 6 months later, while the other half will receive immediate sham therapy followed by cellular therapy 6 months later. Participants will be followed for a total of 2 years.

    at UC Davis

  • A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

    Sorry, in progress, not accepting new patients

    This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).

    at UCSD

  • Clinical Trial of Stem Cell Use in Vision Loss

    “We hope to learn more about the safety and feasibility of using your own (autologous) stem cells extracted from your bone marrow.”

    Sorry, accepting new patients by invitation only

    This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.

    at UC Davis

Our lead scientists for Retinal Vein Occlusion research studies include .

Last updated: